ClinicalTrials.gg
Not yet recruitingNCT05265052Updated Mar 11, 2026

3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

A Phase 2 interventional study of 3D1002 (50 mg)(Phase IIa) and 3D1002 (100 mg)(Phase IIa) in Cancer Pain, sponsored by 3D Medicines. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by 3D Medicines · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing oxycodone in Cancer Pain — 1 open to participants now, 1 under way, none of them phase 3. Oxycodone · Cancer Pain.

Planned enrollment
5th of 10
177 · median 153
Started
2026
the only one that year
Phase 2
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
3D Medicines

Among the 10 studies testing oxycodone in Cancer Pain, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 2, and was the 10th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

1 of the 10 studies testing oxycodone in Cancer Pain is open now.

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing oxycodone in Cancer Pain, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.

Read the detailed description

The investigational product in this study, 3D1002, is a selective antagonist of prostaglandin E2 receptor subtype 4 (EP4). The study is composed of two stages. Phase IIa stage is to assess the safety and efficacy of 3D1002 administered at doses of 50, 100 or 150 mg every 12 hour (q12h) for patients with moderate to severe cancer pain, and to determine the optimal recommended dose for further studies. Phase IIb stage is to evaluate the difference in the efficacy and safety of 3D1002 combined with OxyContin and OxyContin alone in treatment of patients with moderate to severe cancer pain.

03

Conditions studied

  • Cancer Pain

Browse trials for

Keywords

  • Cancer pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must sign the in person prior to beginning any screening procedure.
  2. Age ≥18, both male and female.
  3. Subjects with a malignant tumor confirmed by histopathology or cytology.
  4. Weight ≥40 kg at screening period.
  5. Subjects have relatively stable cancer pain and require continuous analgesic medications (estimated treatment duration ≥2 weeks), as assessed by the investigator.
  6. Estimated ≥3 months.
  7. Subjects are willing to not use any analgesic other than those specified in the study during the study treatment period.
  8. PS score is 0-3.
  9. Have adequate organ and bone marrow function.
  10. The mean NRS scores per day during the are ≥4.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to any of the active ingredients or of the study drug, or have a history of allergy to other opioids or non-steroidal anti-inflammatory drugs (NSAIDs) and their related ingredients.
  2. Have a persistent pain resulted from other medical conditions or unknown causes.
  3. Subjects presenting with emergency symptoms such as intestinal obstruction/perforation, spinal cord compression, epidural , or fracture.
  4. Subjects with known active/symptomatic central nervous system metastasis and/or cancerous meningitis.
  5. Subjects plan to be treated with >10 mg/ day of prednisone or equivalent systemic during the study period.
  6. Have a history of gastrointestinal bleeding or perforation.
  7. Have a positive result of fecal occult blood test during screening period.
  8. Have a history of serious cardiovascular diseases.
  9. Have a history of an acute ischemic or hemorrhagic stroke within 6 months prior to screening.
  10. Have a history of significant psychiatric disorders, such as schizophrenia and depression.
  11. Subjects plan to receive radiotherapy, surgery, or a new regimen of systemic antitumor agents during the study treatment period (D1-D15).
  12. Subjects have a history of alcohol abuse or drug abuse including opioids.
  13. Subjects have significant opioid .
  14. Pregnant or lactating women.
  15. Subjects with other diseases that affect the oral administration or absorption of drugs.
  16. Subjects are currently participating in another clinical study.
  17. Other conditions deemed by the investigator to be inappropriate for participation in this study, such as poor compliance.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    3D1002 50 mg group (Phase IIa)

    3D1002 is given 50 mg twice a day for 2 weeks.

    Drug: 3D1002 (50 mg)(Phase IIa)

  • Experimental
    3D1002 100 mg group (Phase IIa)

    3D1002 is given 100 mg twice a day for 2 weeks.

    Drug: 3D1002 (100 mg)(Phase IIa)

  • Experimental
    3D1002 150 mg group (Phase IIa)

    3D1002 is given 150 mg twice a day for 2 weeks.

    Drug: 3D1002 (150 mg)(Phase IIa)

  • Experimental
    3D1002 monotherapy group (Phase IIb)

    3D1002 at recommended dose plus mimic OxyContin tables, will be given twice a day for 2 weeks.

    Drug: 3D1002 monotherapy (Phase IIb)

  • Experimental
    OxyContin monotherapy group (Phase IIb)

    OxyContin initiating at 10mg per dose plus mimic 3D1002 tablets, will be given twice a day for 2 weeks.

    Drug: OxyContin monotherapy (Phase IIb)

  • Experimental
    3D1002 + OxyContin group (Phase IIb)

    3D1002 at recommended dose plus OxyContin initiating at 10 mg per dose, will be given twice a day for 2 weeks.

    Drug: 3D1002 + OxyContin (Phase IIb)

Interventions

  • Drug3D1002 (50 mg)(Phase IIa)

    1 tablet of 3D1002 per oral dose

  • Drug3D1002 (100 mg)(Phase IIa)

    2 tablets of 3D1002 per oral dose

  • Drug3D1002 (150 mg)(Phase IIa)

    3 tablets of 3D1002 per oral dose

  • Drug3D1002 monotherapy (Phase IIb)

    3D1002 is administered at recommended dose with mimic OxyContin tablets.

  • OxyContin is administered at an initial dose of 10 mg per dose with mimic 3D1002 tablets.

  • Drug3D1002 + OxyContin (Phase IIb)

    3D1002 is administered at recommended dose, and OxyContin is administered at an initial dose of 10 mg per dose.

06

What researchers measure

Primary outcomes

  1. Sum of pain intensity difference in the Numeric Rating Scale (NRS) within 14 days after the first study drug treatment (SPID14)

    ①Average pain intensity is calculated daily for the past 24 hours using the NRS (0 = No pain, 10 = Worst pain imaginable). ②PID (pain intensity difference): Baseline pain intensity score (for the day prior to the day of randomization) minus pain intensity score at each given day.③SPID: the sum of the pain intensity difference generated daily from day 1 to the designated day.

    Time frame: 1 to 14 days after receiving study treatment

Secondary outcomes

  1. Proportion of subjects who achieve effective pain control

    Effective pain control: mean NRS score within 0-3 points and episode of breakthrough pain ≤ 2 times in 24 hours

    Time frame: 1 to 14 days after receiving study treatment

  2. Time to achieve effective pain control

    Time frame: 1 to 14 days after receiving study treatment

  3. Time-specific pain intensity difference(PID)

    Time frame: 1 to 14 days after receiving study treatment

  4. Sum of pain intensity difference (SPID) in the NRS within 3,5 and 7 days post-treatment

    Time frame: from day 1 to 3, 5 and 7 after receiving study treatment, respectively

  5. Time-specific subject self-rated pain relief based on Brief Pain Inventory Short Form (BPI-SF) Questionnaire Item 8

    The pain relief is assessed daily for the past 24 hours based on the percentage of relief from baseline, ranging from 0 (no relief) to 100% (complete relief).

    Time frame: 1 to 14 days after receiving study treatment

  6. Sum of subject self-rated pain relief based on BPI-SF Questionnaire Item 8 within 3,5,7 and 14 days post-treatment

    Time frame: from day 1 to 3, 5, 7 and 14 after receiving study treatment, respectively

  7. Proportion of subjects with pain response over 7 and 14 days after treatment

    Pain response: at least 30% and 50% decrease in pain intensity NRS score from baseline.

    Time frame: 1 to 14 days after receiving study treatment

  8. Time to pain response

    Time frame: 1 to 14 days after receiving study treatment

  9. The number of breakthrough pain episodes and rescue dose of immediate-release oxycodone over 7 and 14 days after treatment;

    Time frame: 1 to 14 days after receiving study treatment

  10. Time-specific oxycodone dose, including immediate-release oxycodone capsules and sustained-release oxycodone tablets (the latter is only applicable for phaseⅡb)

    Time frame: 1 to 14 days after receiving study treatment

  11. Total dose of oxycodone over 3, 7, and 14 days post-treatment

    Time frame: 1 to 14 days after receiving study treatment

  12. Patient's global impression of change (PGI-C) over 7 and 14 days after treatment (for phase IIb only)

    PGI-C is a participant rated instrument to measure participant's change in overall status of general condition including pain on a 7-point scale, with 1 being "very much improved" and 7 being "very much worse".

    Time frame: 1 to 14 days after receiving study treatment

  13. Frequency and severity of adverse events during treatment

    Time frame: 1 to 14 days after receiving study treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2022
First posted
Mar 3, 2022
StartEst.
Dec 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05265052
Lead sponsor
3D Medicines
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Dec 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

Qiling Huang
Contact
qiling.huang@3d-medicines.com
18312677976
Suxia Luo
principal investigator · Henan Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion